PARIS UCB and Sanofi-Aventis’ new once-daily medication used to treat indoor and outdoor allergies, is now available by prescription in the United States, the companies said Tuesday.
Xyzal is an oral antihistamine that has been shown to provide powerful allergy symptom relief, and is approved for use in adults and children 6 years and older.
“Allergy patients need a prescription treatment option that works quickly to relieve their suffering,” said Michael Blaiss, clinical professor of pediatrics and medicine at the University of Tennessee Health Science Center in Memphis, Tennessee. “It is important for people living with allergies to work with their physician to develop an appropriate allergy treatment plan that will effectively reduce their symptoms.”
The Food and Drug Administration approved Xyzal in May. Last year, UCB and Sanofi-Aventis entered into an agreement to launch and co market Xyzal in the United States.
Xyzal is currently marketed in more than 80 countries worldwide, including the European Union. The FDA approval is based primarily upon the results of eight randomized, placebo-controlled clinical trials involving over 2,000 patients.